iconstar paper   HIV Articles  
Back grey arrow rt.gif
Fact Sheet: HHS Provides Resources on Ways Communities Can Stay Protected from Mpox in Advance of Summer Months
[On May 18, 2023, CDC issued in its Morbidity and Mortality Weekly Report (MMWR) the results of two studies highlighting the effectiveness of the JYNNEOS vaccine in preventing mpox disease. Read more here.]
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022 – March 31, 2023
What is already known about this topic?

Real-world vaccine effectiveness (VE) estimates for JYNNEOS vaccine against monkeypox (mpox) are limited. To date, no VE estimates by route of administration or for immunocompro-mised persons have been published.
What is added by this report?
In this study, adjusted VE was 75% for 1 dose and 86% for 2 doses of JYNNEOS vaccine, indicating substantial protection against mpox, irrespective of route of administration or immunocompromise status.
What are the implications for public health practice?
Persons at high risk for mpox exposure should be vaccinated with the recommended 2-dose JYNNEOS series.
Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022
What is already known about this topic?

The JYNNEOS vaccine was deployed in a national and state vaccination campaign during the 2022 monkeypox (mpox) outbreak. Postexposure prophylaxis and vaccination of persons at highest risk (primarily men who have sex with men) were prioritized. Evidence of vaccine effectiveness (VE) from con¬trolled studies has been limited.
What is added by this report?
A comparison of men aged ≥18 years who received a diagnosis of mpox during July 24–October 31 in New York to controls with rectal gonorrhea or primary syphilis, based on systematically collected surveillance data, found adjusted combined 1-dose (received ≥14 days earlier) or 2-dose VE of 75.7%.
What are the implications for public health practice?
These findings support recommended 2-dose JYNNEOS vaccination consistent with CDC and New York State Department of Health guidance.
The CDC Domestic Mpox Response - United States, 2022-2023

The MMWR also includes an overview of the first year of the response to the U.S. mpox outbreak. The article reviews lessons learned to improve response and future readiness, and previews continued mpox response and prevention activities as local viral transmission continues in multiple U.S. jurisdictions.
What We Know About the Virus:
Mpox is a disease that can cause flu-like symptoms and a rash. Based on currently available data, the vast majority of mpox cases in this outbreak have been associated with close skin-to-skin contact associated with sex between men.
Chicago has recently reported a new cluster of mpox cases after nearly three months with almost no mpox cases reported. Some of the cases are in people who have been vaccinated for mpox, and all are mild. The Centers for Disease Control and Prevention (CDC) is aware of these new cases and is working closely with Howard Brown Health, the Chicago Department of Health, and the local community to investigate these new cases and limit the size of this cluster.
How to Keep Yourself Safe:
Make sure that you receive two doses of the mpox vaccine if you are considered to be at-risk for mpox. If you only got one shot, it's never too late to get the second dose. If you are at risk for mpox but haven't received your two-dose vaccine yet, temporarily changing some parts of your sex life might reduce the risk of exposure to the virus. Maintain those changes between your first and second shots of the vaccine since it takes two weeks after the second shot to achieve the highest protection. Knowing how mpox is transmitted allows you to make informed decisions about your sex life to further reduce your risk of exposure.
Seek health care and get tested if you have a rash, even if you have been previously vaccinated or had the infection. For more information on where to find testing, vaccines, or treatment, visit CDC's mpox website.

  iconpaperstack View Older Articles   Back to Top   www.natap.org